Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery

Huanyu Dou, Christopher J. Destache, Justin R. Morehead, R. Lee Mosley, Michael D. Boska, Jeffrey Kingsley, Santhi Gorantla, Larisa Poluektova, Jay A. Nelson, Mahesh Chaubal, Jane Werling, James Kipp, Barrett E. Rabinow, Howard E. Gendelman

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Complex dosing regimens, costs, side effects, biodistribution limitations, and variable drug pharmacokinetic patterns have affected the long-term efficacy of antiretroviral medicines. To address these problems, a nanoparticle indinavir (NP-IDV) formulation packaged into carrier bone marrow-derived macrophages (BMMs) was developed. Drug distribution and disease outcomes were assessed in immune-competent and human immunodeficiency virus type 1 (HIV-1)-infected humanized immune-deficient mice, respectively. In the former, NP-IDV formulation contained within BMMs was adoptively transferred. After a single administration, single-photon emission computed tomography, histology, and reverse-phase-high-performance liquid chromatography (RP-HPLC) demonstrated robust lung, liver, and spleen BMMs and drug distribution. Tissue and sera IDV levels were greater than or equal to 50 μM for 2 weeks. NP-IDV-BMMs administered to HIV-1-challenged humanized mice revealed reduced numbers of virus-infected cells in plasma, lymph nodes, spleen, liver, and lung, as well as, CD4+ T-cell protection. We conclude that a single dose of NP-IDV, using BMMs as a carrier, is effective and warrants consideration for human testing.

Original languageEnglish
Pages (from-to)2827-2835
Number of pages9
JournalBlood
Volume108
Issue number8
DOIs
StatePublished - Oct 15 2006

Fingerprint

Macrophages
Indinavir
Drug delivery
Nanoparticles
Bone
Viruses
Pharmaceutical Preparations
Liver
HIV-1
Spleen
Single photon emission computed tomography
Lung
Histology
Pharmacokinetics
Cytoprotection
T-cells
High performance liquid chromatography
Plasma Cells
Single-Photon Emission-Computed Tomography
Medicine

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., ... Gendelman, H. E. (2006). Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood, 108(8), 2827-2835. https://doi.org/10.1182/blood-2006-03-012534

Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. / Dou, Huanyu; Destache, Christopher J.; Morehead, Justin R.; Mosley, R. Lee; Boska, Michael D.; Kingsley, Jeffrey; Gorantla, Santhi; Poluektova, Larisa; Nelson, Jay A.; Chaubal, Mahesh; Werling, Jane; Kipp, James; Rabinow, Barrett E.; Gendelman, Howard E.

In: Blood, Vol. 108, No. 8, 15.10.2006, p. 2827-2835.

Research output: Contribution to journalArticle

Dou, H, Destache, CJ, Morehead, JR, Mosley, RL, Boska, MD, Kingsley, J, Gorantla, S, Poluektova, L, Nelson, JA, Chaubal, M, Werling, J, Kipp, J, Rabinow, BE & Gendelman, HE 2006, 'Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery', Blood, vol. 108, no. 8, pp. 2827-2835. https://doi.org/10.1182/blood-2006-03-012534
Dou, Huanyu ; Destache, Christopher J. ; Morehead, Justin R. ; Mosley, R. Lee ; Boska, Michael D. ; Kingsley, Jeffrey ; Gorantla, Santhi ; Poluektova, Larisa ; Nelson, Jay A. ; Chaubal, Mahesh ; Werling, Jane ; Kipp, James ; Rabinow, Barrett E. ; Gendelman, Howard E. / Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. In: Blood. 2006 ; Vol. 108, No. 8. pp. 2827-2835.
@article{d9f136faff5146cf97a32d87f4ed6ede,
title = "Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery",
abstract = "Complex dosing regimens, costs, side effects, biodistribution limitations, and variable drug pharmacokinetic patterns have affected the long-term efficacy of antiretroviral medicines. To address these problems, a nanoparticle indinavir (NP-IDV) formulation packaged into carrier bone marrow-derived macrophages (BMMs) was developed. Drug distribution and disease outcomes were assessed in immune-competent and human immunodeficiency virus type 1 (HIV-1)-infected humanized immune-deficient mice, respectively. In the former, NP-IDV formulation contained within BMMs was adoptively transferred. After a single administration, single-photon emission computed tomography, histology, and reverse-phase-high-performance liquid chromatography (RP-HPLC) demonstrated robust lung, liver, and spleen BMMs and drug distribution. Tissue and sera IDV levels were greater than or equal to 50 μM for 2 weeks. NP-IDV-BMMs administered to HIV-1-challenged humanized mice revealed reduced numbers of virus-infected cells in plasma, lymph nodes, spleen, liver, and lung, as well as, CD4+ T-cell protection. We conclude that a single dose of NP-IDV, using BMMs as a carrier, is effective and warrants consideration for human testing.",
author = "Huanyu Dou and Destache, {Christopher J.} and Morehead, {Justin R.} and Mosley, {R. Lee} and Boska, {Michael D.} and Jeffrey Kingsley and Santhi Gorantla and Larisa Poluektova and Nelson, {Jay A.} and Mahesh Chaubal and Jane Werling and James Kipp and Rabinow, {Barrett E.} and Gendelman, {Howard E.}",
year = "2006",
month = "10",
day = "15",
doi = "10.1182/blood-2006-03-012534",
language = "English",
volume = "108",
pages = "2827--2835",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery

AU - Dou, Huanyu

AU - Destache, Christopher J.

AU - Morehead, Justin R.

AU - Mosley, R. Lee

AU - Boska, Michael D.

AU - Kingsley, Jeffrey

AU - Gorantla, Santhi

AU - Poluektova, Larisa

AU - Nelson, Jay A.

AU - Chaubal, Mahesh

AU - Werling, Jane

AU - Kipp, James

AU - Rabinow, Barrett E.

AU - Gendelman, Howard E.

PY - 2006/10/15

Y1 - 2006/10/15

N2 - Complex dosing regimens, costs, side effects, biodistribution limitations, and variable drug pharmacokinetic patterns have affected the long-term efficacy of antiretroviral medicines. To address these problems, a nanoparticle indinavir (NP-IDV) formulation packaged into carrier bone marrow-derived macrophages (BMMs) was developed. Drug distribution and disease outcomes were assessed in immune-competent and human immunodeficiency virus type 1 (HIV-1)-infected humanized immune-deficient mice, respectively. In the former, NP-IDV formulation contained within BMMs was adoptively transferred. After a single administration, single-photon emission computed tomography, histology, and reverse-phase-high-performance liquid chromatography (RP-HPLC) demonstrated robust lung, liver, and spleen BMMs and drug distribution. Tissue and sera IDV levels were greater than or equal to 50 μM for 2 weeks. NP-IDV-BMMs administered to HIV-1-challenged humanized mice revealed reduced numbers of virus-infected cells in plasma, lymph nodes, spleen, liver, and lung, as well as, CD4+ T-cell protection. We conclude that a single dose of NP-IDV, using BMMs as a carrier, is effective and warrants consideration for human testing.

AB - Complex dosing regimens, costs, side effects, biodistribution limitations, and variable drug pharmacokinetic patterns have affected the long-term efficacy of antiretroviral medicines. To address these problems, a nanoparticle indinavir (NP-IDV) formulation packaged into carrier bone marrow-derived macrophages (BMMs) was developed. Drug distribution and disease outcomes were assessed in immune-competent and human immunodeficiency virus type 1 (HIV-1)-infected humanized immune-deficient mice, respectively. In the former, NP-IDV formulation contained within BMMs was adoptively transferred. After a single administration, single-photon emission computed tomography, histology, and reverse-phase-high-performance liquid chromatography (RP-HPLC) demonstrated robust lung, liver, and spleen BMMs and drug distribution. Tissue and sera IDV levels were greater than or equal to 50 μM for 2 weeks. NP-IDV-BMMs administered to HIV-1-challenged humanized mice revealed reduced numbers of virus-infected cells in plasma, lymph nodes, spleen, liver, and lung, as well as, CD4+ T-cell protection. We conclude that a single dose of NP-IDV, using BMMs as a carrier, is effective and warrants consideration for human testing.

UR - http://www.scopus.com/inward/record.url?scp=33750611615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750611615&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-03-012534

DO - 10.1182/blood-2006-03-012534

M3 - Article

VL - 108

SP - 2827

EP - 2835

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -